Property Name |
Property Value |
Unit |
Raw Value |
Raw Unit |
Annotation |
Factor |
Reference |
Absorption |
90.0 |
% |
90 |
% |
PO, oral; fasting; |
|
DRUGBANK |
AUC |
175.0 |
ng.h/ml |
151-199 |
ng.h/ml |
PO, oral; |
|
DRUGBANK |
AUC |
498.5 |
ng.h/ml |
440-557 |
ng.h/ml |
PO, oral; |
|
DRUGBANK |
Bioavailability |
100.0 |
% |
100.0 |
% |
PO, oral; Male, men; normal,healthy; |
|
The Pharmacological Basis of Therapeutics |
C Max |
4.2 |
ng/ml |
3.1-5.3 |
ng/ml |
PO, oral; |
|
DRUGBANK |
C Max |
3.1 |
ng/ml |
2.5-3.6 |
ng/ml |
PO, oral; |
|
DRUGBANK |
C Max |
16.0 |
ng/ml |
16±5 |
ng/ml |
Oral single dose; extended release formulation; normal,healthy; |
|
The Pharmacological Basis of Therapeutics |
T Max |
4.5 |
h |
4-5 |
h |
PO, oral; fasting; |
|
DRUGBANK |
T Max |
6.5 |
h |
6-7 |
h |
PO, oral; food; |
|
DRUGBANK |
T Max |
5.3 |
h |
5.3±0.7 |
h |
Oral single dose; extended release formulation; normal,healthy; |
|
The Pharmacological Basis of Therapeutics |
Clearance |
2.9 |
L/h |
2.88 |
L/h |
|
|
DRUGBANK |
Clearance |
0.0372 |
L/h/kg |
0.62±0.31 |
ml/min/kg |
normal,healthy; Female, women; hydrolysis; hydrolysis; |
Elderly ↓ ;RD, renal impairment, Renal disease,including uremia ↓ ; |
The Pharmacological Basis of Therapeutics |
Clearance |
0.0372 |
L/h/kg |
0.62 |
ml/min/kg |
intravenous injection, IV; human, homo sapiens; |
|
Human Intravenous Pharmacokinetic Dataset |
Volume of Distribution |
16.0 |
L |
16.0 |
L |
intravenous injection, IV; |
|
DRUGBANK |
Volume of Distribution |
0.20 |
L/kg |
0.20±0.06 |
L/kg |
normal,healthy; Female, women; hydrolysis; hydrolysis; |
|
The Pharmacological Basis of Therapeutics |
Volume of Distribution |
0.21 |
L/kg |
0.21 |
L/kg |
intravenous injection, IV; human, homo sapiens; |
|
Human Intravenous Pharmacokinetic Dataset |
Half-life |
14.9 |
h |
14.9±3.9 |
h |
fasting; |
|
DRUGBANK |
Half-life |
6.0 |
h |
5-7 |
h |
elimination half-life; normal,healthy; |
|
DRUGBANK |
Half-life |
11.0 |
h |
9-13 |
h |
normal,healthy; |
|
DRUGBANK |
Half-life |
14.5 |
h |
14-15 |
h |
patients; |
|
DRUGBANK |
Half-life |
6.8 |
h |
6.8±3.5 |
h |
|
RD, renal impairment, Renal disease,including uremia ↑ ;Age ↑ ; |
The Pharmacological Basis of Therapeutics |
Half-life |
14.5 |
h |
~14-15 |
h |
PO, oral; extended release formulation; |
|
The Pharmacological Basis of Therapeutics |
Half-life |
6.8 |
h |
6.8 |
h |
intravenous injection, IV; human, homo sapiens; |
|
Human Intravenous Pharmacokinetic Dataset |
Toxicity LD50 |
650.0 |
mg/kg |
650.0 |
mg/kg |
PO, oral; Rattus, Rat; |
|
DRUGBANK |
Eliminate Route |
76.0 |
% |
76 |
% |
Urinary excretion; PO, oral; |
|
DRUGBANK |
Eliminate Route |
21.0 |
% |
21 |
% |
Faeces excretion; PO, oral; |
|
DRUGBANK |
Eliminate Route |
12.7 |
% |
12.7±3 |
% |
Urinary excretion; Male, men; normal,healthy; human, homo sapiens; Unchanged drug; |
|
The Pharmacological Basis of Therapeutics |
Protein Binding |
96.5 |
% |
94-99 |
% |
|
|
DRUGBANK |
Protein Binding |
99.0 |
% |
99±1 |
% |
Male, men; normal,healthy; human, homo sapiens; |
RD, renal impairment, Renal disease,including uremia ↑ ; |
The Pharmacological Basis of Therapeutics |